The Flying Immunologist

Ph.D. in #Immunology. Avid #aviation enthusiast/pilot, and unashamed #foodie.

[The Flying Immunologist @RudyNazitto]

@gm_mazz It’s giving moverz

[The Flying Immunologist @RudyNazitto]

@adforu @TheHornerLab @IDIatOSU 👀🆒

[The Flying Immunologist @RudyNazitto]

#esgctcellfiecontest

[Endpoints News @endpts]

PacBio was once Illumina's acquisition target. Now it's become a competitor.

@Jared_Whitlock reports on how the sequencing market is evolving:

https://t.co/Zk6oIg1Rw1

[The Flying Immunologist @RudyNazitto]

@ITAAirways I cannot add my Delta Skymiles number to my ITA Airways booking. The website gives an error. Is there a way to fix this?

[The Flying Immunologist @RudyNazitto]

Go @SQZBiotech !

[The Journal of Immunology @J_Immunol]

Congratulations @J_Immunol #20MostRead Scott M. Loughhead @SQZBiotech | #Microfluidic Squeezing Enables #MHCI #AntigenPresentation by Diverse #ImmuneCells to Elicit #CD8TCell Responses with #Antitumor Activity #ReadtheJI #immunology https://t.co/9OvjaTv8GO

[SQZBiotech @SQZBiotech]

At #FOCIS2022 we share preclinical data showing SQZ® TACs led to the presentation of antigen associated w/#celiacdisease, supporting our T cell tolerizing approach. This will support our planned TAC IND submission for celiac disease in the 1st half of 2023 https://t.co/EZHxc34vLg

[SQZBiotech @SQZBiotech]

Thank you to our SQZ social committee for organizing an awesome event to celebrate #PrideMonth!

[SQZBiotech @SQZBiotech]

June is #CancerImmunotherapyMonth. At SQZ Biotech, we recognize the powerful potential of the immune system. Learn more about how we are putting patients’ immune systems to work to fight against their cancer: https://t.co/XXNBXefP8c

[SQZBiotech @SQZBiotech]

A new article in @NatureMedicine highlights @ArmonSharei's discovery of our Cell Squeeze® technology and its potential to provide a new method of drug delivery for autoimmune and infectious diseases: https://t.co/25ImCp1Gtq

[SQZBiotech @SQZBiotech]

We are incredibly excited to welcome Marshelle Smith Warren, MD, as our Chief Medical Officer. Her cell-based therapeutic development experience and global clinical trial background will strengthen our ability to execute on our mission for patients: https://t.co/EqRrho7Nrl

[SQZBiotech @SQZBiotech]

Traditional cell engineering methods often permanently alter cells. In this #HCW episode, learn how transient approaches can create powerful therapeutics without permanently changing the cell – potentially broadening disease applicability & reducing long-term safety risks:

[SQZBiotech @SQZBiotech]

Today at #ASGCT22 we share preclinical data that shows that our SQZ® Point-of-Care manufacturing system could produce our Activating Antigen Carrier (AAC) therapeutic candidate in under 6 hours: https://t.co/hiyfGBc86X #celltherapy

[Armon Sharei @ArmonSharei]

Thrilled to announce a new collaboration with @STEMCELLTech to co-develop a research-use-only microfluidic intracellular delivery system. With the RUO system, our goal is to help drive #celltherapy development in the broader scientific community: https://t.co/hwq9zllFC8

[SQZBiotech @SQZBiotech]

This Thursday, SQZ CEO & Founder @ArmonSharei will participate in a panel on Scientific Innovation: Transferring Technology from Academia as part of @LongwoodLeaders Spring MIT web conference. Learn more: https://t.co/ErSOCPwQKR

[SQZBiotech @SQZBiotech]

.@US_FDA has granted Fast Track Designation to our lead APC candidate, SQZ-PBMC-HPV, for HPV16+ advanced or metastatic solid tumors, creating the potential to bring this important new therapy to patients earlier. Learn more: https://t.co/Q5zlzBipRO

[SQZBiotech @SQZBiotech]

At #AACR22 we're sharing preclinical data on our eAPC platform demonstrating that our multiplexed mRNA engineering of immune cells increased CD8 T cell activity and could potentially increase the number of patients who could benefit from the therapy: https://t.co/4obFERdbXi

[SQZBiotech @SQZBiotech]

At #AACR22, @SQZBiotech will present a poster on the SQZ® eAPC platform and a Trial-in-Progress presentation on our SQZ® AAC candidate: https://t.co/eLWCootsut Cc @cityofhope

[SQZBiotech @SQZBiotech]

Preclinical data published in @FrontImmunol by @SQZBiotech demonstrated that Tolerizing Antigen Carriers (TACs) can induce multiple key mechanisms of antigen-specific tolerance and potentially protect against #Type1diabetes https://t.co/WMkHR0fKdJ Cc @JDRF #celltherapy

[SQZBiotech @SQZBiotech]

Learn more about the science behind @SQZBiotech’s @NIH grant to develop a novel cell therapy for the potential treatment of #Parkinsonsdisease in this #HCW episode on regenerative medicine approaches: